A Study of LY4064912 in Healthy Participants and With Overweight or Obesity

Last updated: April 17, 2026
Sponsor: Eli Lilly and Company
Overall Status: Active - Recruiting

Phase

1

Condition

Diabetes Prevention

Obesity

Hypertriglyceridemia

Treatment

LY4064912

Placebo

Clinical Study ID

NCT07152002
27192
J5L-MC-YHAA
  • Ages 18-65
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The purpose of this study is to evaluate how well LY4064912 is tolerated and what side effects may occur in healthy participants and participants with overweight and obesity - global. The study drug will be administered either subcutaneously (SC) (under the skin) or infusion intravenously (IV) (into a vein in the arm).

Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age is 21-65 years old at Singapore Sites

  • Participants who are overtly healthy as determined by medical evaluation includingmedical history, physical examination, laboratory tests, and cardiac monitoring

Part A: Body Mass Index (BMI) within the range greater than or equal to 21 and less than 30 kilogram per square meter (kg/m²)

Part B: a BMI greater than or equal to 27 and less than 45 kg/m²

Part C: a BMI greater than or equal to 21 and less than 35 kg/m²

  • Parts A and C: Participants must weigh 60 kilograms (kg) or more at screening

  • Have had a less than 5% change in body weight for 3 months before screening

  • Safety laboratory tests are within normal reference range

Exclusion

Exclusion Criteria:

  • Have a history or presence of cardiovascular, respiratory, hepatic, renal,gastrointestinal, endocrine, hematological, or neurological disorders capable ofsignificantly altering the absorption, metabolism, or elimination of drugs; ofconstituting a risk when taking the investigational product; or of interfering withthe interpretation of data

  • Have history of diabetes (except gestational diabetes) or current diagnosis ofdiabetes (any form), or have HbA1c greater than or equal to 6.5% (48 millimole permole (mmol/mol)) at screening

  • Are individuals of childbearing potential (IOCBP).

Study Design

Total Participants: 144
Treatment Group(s): 2
Primary Treatment: LY4064912
Phase: 1
Study Start date:
August 28, 2025
Estimated Completion Date:
November 30, 2026

Connect with a study center

  • Lilly Centre for Clinical Pharmacology

    Singapore, 138623
    Singapore

    Active - Recruiting

  • Lilly Centre for Clinical Pharmacology

    Singapore 1880252, 138623
    Singapore

    Site Not Available

  • Collaborative Neuroscience Network - CNS

    Los Alamitos, California 90720
    United States

    Active - Recruiting

  • Collaborative Neuroscience Network - CNS

    Los Alamitos 5368304, California 5332921 90720
    United States

    Site Not Available

  • ICON Early Phase Services

    San Antonio, Texas 78209
    United States

    Active - Recruiting

  • ICON Early Phase Services

    San Antonio 4726206, Texas 4736286 78209
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.